Total parenteral nutrition-associated cholestasis and risk factors in preterm infants
- PMID: 25253364
- PMCID: PMC4196344
- DOI: 10.4103/1319-3767.141688
Total parenteral nutrition-associated cholestasis and risk factors in preterm infants
Abstract
Background/aim: Development of hepatic dysfunction is a well-recognized complication of total parenteral nutrition in preterm infants. Previous studies reported the incidence of total parenteral nutrition-associated cholestasis and described possible contributing factors to its pathogenesis, but little is done trying to determine its possible predictive risk factors. The aims of this study was to determine the incidence of total parenteral nutrition-associated cholestasis and to develop a possible predictive model for its occurrence.
Patients and methods: A review of medical records of all very low birth weight infants admitted to neonatal intensive care unit at King Khalid University Hospital, Riyadh, Saudi Arabia, between January 2001 and December 2003 was carried out. The infants were divided into two groups: Cholestasis and noncholestasis, based on direct serum bilirubin level >34 μmol/L. A multivariate logistic regression analysis was performed to calculate the statistical significance of risk factors. Receiver-operating characteristic curve was used to determine the optimal cutoff points for the significant risk factors and to calculate their sensitivity and specificity. The level of significance was set at P ≤ 0.05.
Results: A total of 307 patients were included in the analysis. The incidence of cholestasis in the whole population was 24.1% (74 patients). Infants with cholestasis had a lower birth weight, 735.4 ± 166.4 g vs. 1185.0 ± 205.6 g for noncholestasis group (P < 0.001), whereas the mean gestational age for the two groups was 25.4 ± 2.1 week and 28.9 ± 2.1 week, respectively (P < 0.001). The significant risk factors for the development of cholestasis were birth weight (P = 0.006) with an odds ratio of 0.99 [95% confidence interval (CI), 0.98, 0.99]; sensitivity of 92%, specificity of 87%; and total parenteral nutrition duration (P < 0.001) with an odds ratio of 1.18 (95% CI, 1.10, 1.27); sensitivity of 96%, specificity of 89%.
Conclusions: A lower birth weight and longer duration of total parenteral nutrition were strong predictive risk factors for the development of cholestasis in preterm infants.
Conflict of interest statement
References
-
- Naini BV, Lassman CR. Total parenteral nutrition therapy and liver injury: A histopathologic study with clinical correlation. Hum Pathol. 2012;43:826–33. - PubMed
-
- Buchman AL, Iyer K, Fryer J. Parenteral nutrition-associated liver disease and the role for isolated intestine and intestine/liver transplantation. Hepatology. 2006;43:9–19. - PubMed
-
- Peden VH, Witzleben CL, Skelton MA. Total parenteral nutrition. J Pediatr. 1971;78:180–1. - PubMed
-
- Lauriti G, Zani A, Aufieri R, Cananzi M, Chiesa PL, Eaton S, et al. Incidence, prevention, and treatment of parenteral nutrition–associated cholestasis and intestinal failure–associated liver disease in infants and children. A systematic review. JPEN J Parenter Enteral Nutr. 2014;38:70–85. - PubMed
-
- Spencer AU, Yu S, Tracy TF, Aouthmany MM, Llanos A, Brown MB, et al. Parenteral nutrition-associated cholestasis in neonates: Multivariate analysis of the potential protective effect of taurine. JPEN J Parenter Enteral Nutr. 2005;29:337–44. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources